V
VINCIT BIOLOGICS
Rare Hematology Therapeutics
HAGEMIA ASSIST · PATIENT SUPPORT PROGRAM

Guiding access from the very first step.

Hagemia Assist helps eligible patients complete the first steps of program enrollment, provide consent, and stay connected through their patient portal while their prescriber finalizes required documentation.

HAGEMIA

hageman-alpha injection

Recombinant Factor XII replacement therapy

Designed for patients with Factor XII Deficiency, Hagemia is positioned around the “Spark” of the intrinsic coagulation pathway.

PATIENT ASSISTANCE

Hagemia Assist helps simplify enrollment.

A patient-friendly workflow helps eligible patients begin enrollment, provide consent, and route the prescriber portion for completion.

01

Eligibility Assessment

Guided screening for patient support eligibility and required program criteria.

02

Patient Consent

Digital authorization to receive support services and program communications.

03

Prescriber Handoff

Enrollment form routing so the provider can complete clinical and prescription details.

04

Patient Portal Access

Visibility into enrollment status, documents, support updates, and future therapy activity.

BEYOND HAGEMIA

Additional support resources

Explore educational materials and independent support resources that may help patients throughout their treatment journey.

Alternative Funding Resources

Patients may also explore independent non-profit organizations that provide financial assistance for eligible individuals, including travel support and treatment-related expenses.

Independent Assistance Programs Travel, affordability, and support resources
Rare Disease Advocacy Resources Educational and community-based support organizations

Disease State Education

Learn more about Factor XII Deficiency and the “Spark of the Cascade” through patient-friendly educational content and guided learning materials.

Learning Center

Explore simplified visual explanations of the coagulation pathway, Factor XII activity, and treatment support information.